Koganti Sivaramakrishna
The University of Iowa, Internal Medicine , Iowa City , USA.
Mol Membr Biol. 2015;32(2):35-8. doi: 10.3109/09687688.2015.1010619. Epub 2015 Apr 29.
G-Protein Coupled Estrogen Receptor 1 (GPER1), also known as G-Protein Coupled Receptor 30 (GPR30) and initially considered an orphan receptor, has become one of the most important pharmacological targets in cardiovascular research. Since the gene encoding this putative receptor was cloned nearly 20 years ago, researchers have addressed its role in various aspects of physiology, including cardioprotection. Although extensive research has been carried out to understand the role of GPER1 as a pharmacological target to treat cardiovascular diseases, there are few current reviews addressing the overall cardioprotective benefits of this receptor and the signaling intermediates involved. This review considers the origins of GPER1, its cell biology, its physiological and pharmacological roles as a therapeutic target in cardiovascular disease, and what future research on GPER1 might entail. More specifically, the review focuses on GPER1 regulation of Angiotensin Type I Receptor (AT1R) and the role of estrogen receptors, epidermal growth factor receptor (EGFR) and matrix metalloproteinases (MMPs) in bringing about the cardioprotective effects of GPER1. Areas where improved knowledge of GPER1 biology is still needed to better understand the receptor's cardioprotective effects are also discussed.
G蛋白偶联雌激素受体1(GPER1),也被称为G蛋白偶联受体30(GPR30),最初被认为是一种孤儿受体,现已成为心血管研究中最重要的药理学靶点之一。自从大约20年前编码这种假定受体的基因被克隆以来,研究人员已经探讨了它在生理学各个方面的作用,包括心脏保护作用。尽管已经进行了广泛的研究来了解GPER1作为治疗心血管疾病的药理学靶点的作用,但目前很少有综述探讨该受体的整体心脏保护益处以及所涉及的信号转导中间体。本综述考虑了GPER1的起源、其细胞生物学、其作为心血管疾病治疗靶点的生理和药理作用,以及GPER1未来的研究方向。更具体地说,该综述重点关注GPER1对血管紧张素I型受体(AT1R)的调节作用,以及雌激素受体、表皮生长因子受体(EGFR)和基质金属蛋白酶(MMPs)在发挥GPER1心脏保护作用中的作用。还讨论了在哪些方面仍需要进一步了解GPER1生物学知识,以便更好地理解该受体的心脏保护作用。